EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates

Simone Mok iD, Emma Roycroft, Peter R Flanagan, Johannes Wagener, Margaret M Fitzgibbon

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Simone Mok und 4 weiteren Autor:innen. Beteiligte Einrichtung: Irish Mycobacteria Reference Laboratory, St James's Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Innovative New Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

WGS has the potential to detect resistance-associated mutations and guide treatment of MDR TB. However, the knowledge base to confidently interpret mutations associated with the new and repurposed drugs is sparse, and phenotypic drug susceptibility testing is required to detect resistance.

Methods

We screened 900 Mycobacterium tuberculosis complex genomes from Ireland, a low TB incidence country, for mutations in 13 candidate genes and assessed their association with phenotypic resistance to bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Results

We identified a large diversity of mutations in the candidate genes of 195 clinical isolates, with very few isolates associated with phenotypic resistance to bedaquiline (n = 4), delamanid (n = 4) and pretomanid (n = 2). We identified bedaquiline resistance among two drug-susceptible TB isolates that harboured mutations in Rv0678. Bedaquiline resistance was also identified in two MDR-TB isolates harbouring Met146Thr in Rv0678, which dated back to 2007, prior to the introduction of bedaquiline. High-level delamanid resistance was observed in two isolates with deletions in ddn, which were also resistant to pretomanid. Delamanid resistance was detected in two further isolates that harboured mutations in fbiA, but did not show cross-resistance to pretomanid. All isolates were susceptible to linezolid and clofazimine, and no mutations found were associated with resistance.

Conclusions

More studies that correlate genotypic and phenotypic drug susceptibility data are needed to increase the knowledge base of mutations associated with resistance, in particular for pretomanid. Overall, this study contributes to the development of future mutation catalogues for M. tuberculosis complex isolates

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantHumansAntitubercular AgentsClofazimineLinezolidMicrobial Sensitivity TestsDiarylquinolinesMutationGenomicsNitroimidazolesOxazoles

Substanzen

Antitubercular AgentsClofazimineLinezolidDiarylquinolinesOPC-67683NitroimidazolesOxazolespretomanid

Autor:innen und Institutionen

  • Irish Mycobacteria Reference Laboratory, St James's Hospital, Dublin, Ireland.
  • Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, the University of Dublin, St James's Hospital Campus, Dublin, Ireland.

ORCID-Profile: Simone Mok

Förderung

  • Foundation for Innovative New Diagnostics

Zitieren

APA

Mok, S., Roycroft, E., Flanagan, P. R., Wagener, J., & Fitzgibbon, M. M. (2023). Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad252

Vancouver

Mok S, Roycroft E, Flanagan PR, Wagener J, Fitzgibbon MM. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad252

BibTeX
@article{Mok2023,
  author = {Mok, Simone and Roycroft, Emma and Flanagan, Peter R and Wagener, Johannes and Fitzgibbon, Margaret M},
  title = {Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad252}
}
Kostenlos starten →